Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
1. Ascendis Pharma beat EPS loss expectations, reporting a loss of 64 cents. 2. Revenue rose to 173.9 million euros, exceeding estimates thanks to Yorvipath's launch. 3. Yorvipath's early prescription trends are strong with 908 prescriptions as of February 2025. 4. Goldman Sachs maintains a Buy rating, raising the price target to $225 from $200. 5. Insurance challenges may affect Yorvipath's revenue growth in the short term.